Discussion about this post

User's avatar
Joel Sherwood's avatar

Thanks so much. Opera - great question. There's a lot to like there. Good valuation with forward PE at 15 and peg of 0.3. EPS expected to continue higher. High margin and very decent FCF. And apparently good with buybacks and dividends. So all that's good. What doesn't excite me is the ROCE and ROIC. Single digits on average the past 5 years still. And then there's the product, which I get is niche, customizeable, and constantly improving. But I don't personally get what's extra good about Opera vs the big guys, and I don't have any sense about their long-term durability. I also don't like they get a big chunk of revenue from Google, their competitor. I'd say if you know the product well and like it a lot, and see others liking it a lot, then you may be on to something here. Hope this helped. I'll keep them on my radar too now. All the very best and stay in touch. Ps here's a good deep dive for more info: https://welfarecapital.substack.com/p/opera-limited-opra-deep-dive-6

Expand full comment
burnout investor's avatar

Interesting list! Many good names that I´m also following for potential entry's or opportunities to add to Fortnox and Harvia. Some names that you might have missed, hmm... have you looked at Marimekko (FI) or Chemometec (DEN)? From Norway, I recently started looking at Medistim.

Expand full comment
24 more comments...

No posts